Published date:
25/01/2023
Summary:
Strong clinical progress with ongoing ModiFY and SCOPE trials; further safety, immune and clinical response data expected in 2023
Signed licensing agreement with Genmab to develop and commercialise an anti-glycan mAb providing strong commercial validation of the Company's scientific approach and strategy
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces its interim results for the 6 months ended 31 October 2022 and provides a business update on progress achieved to date.
Highlights (including post period):
Vaccines:
